Expression of Annexin A4 in Cancer: A Tissue Microarray Study Involving More than 17,600 Cancers from 148 Tumor Entities.
4 affiliations
- 1Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
- 2Department of General, Visceral, Transplant and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
- 3Institute of Pathology, Clinical Center Osnabrueck, 49076 Osnabrueck, Germany.
- 4Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany.
Abstract
Background/Objectives: Annexin A4 (ANXA4) is one of twelve members of the annexin superfamily that bind membrane phospholipids in a calcium-dependent manner, and which are involved in several processes related to the membrane. Methods: To learn more about the role of ANXA4 in cancer, the ANXA4 expression was analyzed by immunohistochemistry (IHC) on tissue microarrays (TMAs) containing 17,654 tumors and precursor lesions from 148 tumor types. Results: ANXA4 immunostaining was found in 10,858 (83.4%) of 13,017 analyzable tumors, and was considered weak in 10.1%, moderate in 16.6%, and strong in 61.8% of cases. Of 148 tumor categories, 144 showed ANXA4 staining in at least one case and 133 included at least one case with strong staining. Among tumor entities with at least 10 evaluable samples, strong ANXA4 staining in >50.0% of cases was seen in 56 of 120 entities, while absence of staining in >50.0% of cases was seen in 13. Clinically important tumor entities where ANXA4 staining was always positive (>99.5%) included gallbladder adenocarcinoma, cholangiocarcinoma, pancreatic/ampullary, various subtypes of salivary gland tumors, papillary renal cell carcinoma, urothelial carcinoma, squamous and basal cell carcinoma of the skin, and epithelioid mesothelioma. A reduced ANXA4 expression was linked to features of cancer aggressiveness in breast cancer, clear cell renal cell carcinoma, urothelial carcinoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, colorectal adenocarcinoma, and follicular thyroid carcinoma. Conclusions: It is concluded that ANXA4 is abundantly expressed in human malignancies and that a reduced expression may be linked to unfavorable disease characteristics in many important tumor entities.
Related
- Multipath interaction network of annexin A2: multifaceted regulation and translational perspectives in neurological diseases
- Resistance to membrane damage enhances metastatic potential of breast cancer cells via dysregulated phospholipid profiles and annexin-mediated repair
- STiLE: automated tissue microarray dearraying for spatial transcriptomics.
- Mapping the exposome of Zimbabwean preschool-aged children using a novel peptide microarray approach
- The N-terminus of alpha-1 giardin, a parasitic annexin orthologue, is essential for oligomerization and lipid-binding activity
BibTeX
@article{volkel2026expression,
title = {{Expression of Annexin A4 in Cancer: A Tissue Microarray Study Involving More than 17,600 Cancers from 148 Tumor Entities.}},
author = {Cosima Völkel and Nayma Malas and Fiete Gehrisch and Anne Menz and Florian Lutz and Viktoria Chirico and Florian Viehweger and David Dum and Ria Schlichter and Andrea Hinsch and Christoph Fraune and Christian Bernreuther and Seyma Büyücek and Martina Kluth and Claudia Hube-Magg and Georgia Makrypidi-Fraune and Nina Schraps and Katharina Möller and Andreas M Luebke and Patrick Lebok and Guido Sauter and Maximilian Lennartz and Till S Clauditz and Andreas H Marx and Ronald Simon and Eike Burandt and Natalia Gorbokon and Maria Christina Tsourlakis and Sarah Minner and Till Krech and Morton Freytag and Viktor Reiswich and Stefan Steurer},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193077},
url = {https://europepmc.org/article/MED/42882772},
note = {CC BY},
}
RIS
TY - JOUR
TI - Expression of Annexin A4 in Cancer: A Tissue Microarray Study Involving More than 17,600 Cancers from 148 Tumor Entities.
AU - Cosima Völkel
AU - Nayma Malas
AU - Fiete Gehrisch
AU - Anne Menz
AU - Florian Lutz
AU - Viktoria Chirico
AU - Florian Viehweger
AU - David Dum
AU - Ria Schlichter
AU - Andrea Hinsch
AU - Christoph Fraune
AU - Christian Bernreuther
AU - Seyma Büyücek
AU - Martina Kluth
AU - Claudia Hube-Magg
AU - Georgia Makrypidi-Fraune
AU - Nina Schraps
AU - Katharina Möller
AU - Andreas M Luebke
AU - Patrick Lebok
AU - Guido Sauter
AU - Maximilian Lennartz
AU - Till S Clauditz
AU - Andreas H Marx
AU - Ronald Simon
AU - Eike Burandt
AU - Natalia Gorbokon
AU - Maria Christina Tsourlakis
AU - Sarah Minner
AU - Till Krech
AU - Morton Freytag
AU - Viktor Reiswich
AU - Stefan Steurer
PY - 2026
DA - 2026/09/22
JO - Cancers
DO - 10.3390/cancers18193077
UR - https://europepmc.org/article/MED/42882772
AB - Background/Objectives: Annexin A4 (ANXA4) is one of twelve members of the annexin superfamily that bind membrane phospholipids in a calcium-dependent manner, and which are involved in several processes related to the membrane. Methods: To learn more about the role of ANXA4 in cancer, the ANXA4 expression was analyzed by immunohistochemistry (IHC) on tissue microarrays (TMAs) containing 17,654 tumors and precursor lesions from 148 tumor types. Results: ANXA4 immunostaining was found in 10,858 (83.4%) of 13,017 analyzable tumors, and was considered weak in 10.1%, moderate in 16.6%, and strong in 61.8% of cases. Of 148 tumor categories, 144 showed ANXA4 staining in at least one case and 133 included at least one case with strong staining. Among tumor entities with at least 10 evaluable samples, strong ANXA4 staining in >50.0% of cases was seen in 56 of 120 entities, while absence of staining in >50.0% of cases was seen in 13. Clinically important tumor entities where ANXA4 staining was always positive (>99.5%) included gallbladder adenocarcinoma, cholangiocarcinoma, pancreatic/ampullary, various subtypes of salivary gland tumors, papillary renal cell carcinoma, urothelial carcinoma, squamous and basal cell carcinoma of the skin, and epithelioid mesothelioma. A reduced ANXA4 expression was linked to features of cancer aggressiveness in breast cancer, clear cell renal cell carcinoma, urothelial carcinoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, colorectal adenocarcinoma, and follicular thyroid carcinoma. Conclusions: It is concluded that ANXA4 is abundantly expressed in human malignancies and that a reduced expression may be linked to unfavorable disease characteristics in many important tumor entities.
SN - 2072-6694
ER -